Geron (NASDAQ:GERN – Get Free Report) is set to announce its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.
Geron (NASDAQ:GERN – Get Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Geron had a negative return on equity of 63.33% and a negative net margin of 77,691.14%. The firm’s revenue for the quarter was down 77.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.10) EPS. On average, analysts expect Geron to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Geron Stock Performance
Shares of GERN stock traded down $0.14 during trading hours on Tuesday, reaching $4.00. 7,302,152 shares of the company’s stock were exchanged, compared to its average volume of 11,181,813. The company has a market cap of $2.19 billion, a P/E ratio of -12.55 and a beta of 0.61. Geron has a 1 year low of $1.64 and a 1 year high of $4.30. The company’s 50 day moving average is $2.93 and its two-hundred day moving average is $2.32. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.16 and a quick ratio of 3.16.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Geron
About Geron
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Recommended Stories
- Five stocks we like better than Geron
- Health Care Stocks Explained: Why You Might Want to Invest
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Hilton Demonstrates Asset Light is Right for Investors
- What is the NASDAQ Stock Exchange?
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.